[1. Rees PJ, Clark TJ, Moren F. The importance of particle size in responses to inhaled bronchodilators. Eur. J. Respir. Dis. 1982; 63:73-8.]Search in Google Scholar
[2. Zanen P, Go TL, Lammers JWJ. The optimal particle size for β2-adrenergic aerosols in mild asthmatics. Int. J. Pharm. 1994; 107: 211-7.]Search in Google Scholar
[3. Zanen P, Go TL, Lammers JWJ. Optimal particle size for β2-agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51: 977-80.10.1136/thx.51.10.977]Search in Google Scholar
[4. Chrystyn, H., Is total particle dose more important than particle distribution? Respir. Med. 1997; 91:17-9.]Search in Google Scholar
[5. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981; 36:52-5.10.1136/thx.36.1.52]Search in Google Scholar
[6. Mechlor R, Biddiscomb MF, Mak VHF, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and inpatients with reversible airflow obstruction. Thorax. 1993; 48:506-11.10.1136/thx.48.5.506]Search in Google Scholar
[7. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: The bridge between in vitro and clinical evaluations for inhaled drug products?. Int J Pharm. 2000; 208:49-60.10.1016/S0378-5173(00)00538-X]Search in Google Scholar
[8. Tomlinson HS, Corlett SA, Allen MB, Chrystyn H. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. Br J Clin Pharm. 2005; 60:605-10.10.1111/j.1365-2125.2005.02499.x]Search in Google Scholar
[9. National Heart Lung and Blood Institute. National asthma education and prevention program expert panel report 3: guidelines for the diagnosis and management for asthma. 2007. [cited 2010 April 8]. Available from: http://www.nhlbi.nih.gov.]Search in Google Scholar
[10. Weda M, Zanen P, De Boer AH, Gjaltema D, Ajaoud A, Barends DM, et al. Equivalence testing of salbutamol dry powder inhalers: In vitro impaction results versus in vivo efficacy. In J Pharm. 2002; 249:247-55.10.1016/S0378-5173(02)00533-1]Search in Google Scholar
[11. British Pharmacopoeia. 2010. London: The Stationery Office (CD-ROM accessed 1 January 2010).]Search in Google Scholar
[12. Srichana T, Suedee R, Srisudjai P. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie. 2003; 58:125-9.]Search in Google Scholar
[13. National Asthma Council Australia. Asthma Management Handbook (Online). National Asthma Council Australia Ltd. [cited 2010 April 8].Available from: http://www.nationalasthma.org.au/cms/index.php]Search in Google Scholar
[14. International Conference on Harmonization (ICH). Good Clinical Practice Guidelines, Minister of Public Health, Therapeutic Directorate, Health Canada, Ontario; 1996.]Search in Google Scholar
[15. Srichana T, Suedee R, Tanmanee N, Muanpanarai D, Marriott C. The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation. Pulm.Pharmacol. 2007; 20:36-45.]Search in Google Scholar
[16. Srichana T, Brain A, Marriot C. A study of Drug-carrier interaction in dry powder inhaler formulation using the Andersen Cascade Impactor, X-ray microanalysis and time of flight aerosol beam spectrometry (TOFABS). Chem. Pharm. Bull. 2000; 48:167-74.]Search in Google Scholar